País: Irlanda
Idioma: anglès
Font: HPRA (Health Products Regulatory Authority)
BICALUTAMIDE
PCO Manufacturing
50 Milligram
Film Coated Tablet
2004-07-02
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Casodex 50mg Film-Coated Tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 50mg bicalutamide. Excipients: Contains Lactose Monohydrate For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablets Product imported from Greece and Italy: Round, white, biconvex, intagliated with ‘CDX50’ on one face and a logo on the reverse. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of advanced prostate cancer in combination with LHRH analogue therapy or surgical castration. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Adult males: one tablet (50mg) once a day. (including the elderly) Treatment with Casodex should be started at the same time as treatment with a LHRH analogue or surgical castration. Children: Casodex is contra-indicated in children Renal Impairment: No dosage adjustment is necessary for patients with renal impairment Hepatic Impairment: No dosage adjustment is necessary for patients with mild hepatic impairment. Increased accumulation may occur in patients with moderate to severe hepatic impairment _(see under 4.4 “Special warnings and_ _special precautions for use”)._ 4.3 CONTRAINDICATIONS Casodex is contraindicated in females and children. Casodex must not be given to any patient who has shown a hypersensitivity reaction to its use. Co-administration of terfenadine, astemizole or cisapride with Casodex is contraindicated (see section 4.5). IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 14/04/2011_ _CRN 2091269_ _page number: 1_ 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Initiation of treatment should be under the direct supervision of a specialist. Casodex is extens Llegiu el document complet